Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2).

Authors

Volker Moebus

Klinikum Frankfurt Hoechst, Frankfurt, Germany

Volker Moebus , Helmut Forstbauer , Grischa Wachsmann , Andreas Schneeweiss , Angelika Ober , Ekkehard von Abel , Petra Krabisch , Heinz-Gert Hoeffkes , Karin Kast , Bernd Christensen , Michael Niedermeier , Mustafa Deryal , Christoph Uleer , Yvonne Fauster , Thomas Goehler , Sibylle Loibl , Valentina Nekljudova , Gunter Von Minckwitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Cytotoxic Chemotherapy

Clinical Trial Registration Number

NCT01690702

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS1137)

DOI

10.1200/jco.2013.31.15_suppl.tps1137

Abstract #

TPS1137

Poster Bd #

33D

Abstract Disclosures

FEATURED

Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2).

Authors

Volker Moebus

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): Efficacy analysis of the GEICAM/2003-10 trial.

Poster

GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).

Poster

Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.

Poster

Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression.